MLNT

Melinta Therapeutics, Inc. Common Stock

MLNT

Overview Fund Trends Analyst Outlook Journalist POV

Delisted

MLNT was delisted on the 10th of January, 2020.

Back to rankings

Positive

Neutral

Negative

Sentiment 3-Months

Positive

Neutral 0%

Negative

CorMedix to Buy Melinta Therapeutics for $300 Million

The buyer said the deal adds six marketed infectious-disease products to its offerings.

CorMedix to Buy Melinta Therapeutics for $300 Million

See News Rankings